Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 3/20 | 0.32 |
| ▸ | LPL | P06858 | 4/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 4/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | HTR1F | P30939 | 1/20 | 0.31 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7906093 | 0.88 | HTR1A (0.32) | AVPR1ALPLLIPGHTR1AHTR1D | |
| SCHEMBL12129039 | 0.88 | HTR1A (0.32) | AVPR1ALPLLIPGHTR1AHTR1D | |
| SCHEMBL12130905 | 0.85 | AVPR1A (0.30) | AVPR1AAVPR1B | |
| SCHEMBL16934779 | 0.79 | HTR2C (0.37) | LPLLIPGIDO1TDO2NOS3 | |
| SCHEMBL426125 | 0.78 | CYP11B1 (0.47) | LPLLIPGIDO1TDO2 | |
| SCHEMBL14647203 | 0.77 | CHRM2 (0.38) | AVPR1AHTR1AHTR1DHTR1FAVPR1B | |
| SCHEMBL23962763 | 0.75 | KRAS (0.33) | LPLLIPG | |
| SCHEMBL31430454 | 0.75 | KRAS (0.33) | LPLLIPG | |
| SCHEMBL24610257 | 0.75 | LPL (0.39) | LPLLIPGNOS3NOS1 | |
| SCHEMBL24629797 | 0.74 | GAA (0.45) | AVPR1AHTR1AHTR1DHTR1FNOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346505-B1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2346505-B1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2014-04-23 | — | — | EP | disclosed |
| US-8697689-B2 | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-04-15 | — | — | US | disclosed |
| US-8691813-B2 | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-04-08 | — | — | US | disclosed |
| US-8691813-B2 | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors | Janssen Pharmaceuticals, Inc. (US) | 2014-04-08 | — | — | US | disclosed |
| EP-2373649-B1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | JANSSEN PHARMACEUTICALS INC (US) | 2013-01-23 | — | — | EP | disclosed |
| US-20120035167-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Janssen Pharmaceuticals, Inc. | 2012-02-09 | — | — | US | disclosed |
| US-20120035167-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Janssen Pharmaceuticals, Inc. | 2012-02-09 | — | — | US | disclosed |
| US-20110275624-A1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. | 2011-11-10 | — | — | US | disclosed |
| WO-2010060589-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010060589-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010043396-A1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275624-A1 | INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM2, GRM1, GRM5 | AVPR1A 326/4885LPL 3663/4885LIPG 4342/4885 |
| US-20120035167-A1 | INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM2, GRM5, GRIA2 | AVPR1A 581/4885LPL 4185/4885LIPG 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.